Experimental HBV Drugs
Experimental HBV Drugs
AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. 
Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine
- Details
- Category: HBV Treatment
- Published on Friday, 28 October 2011 00:00
- Written by Press Release
Gilead Sciences and GlobeImmune announced this week that they will collaborate on the development and commercialization of a hepatitis B virus (HBV) therapeutic vaccine using GlobeImmune's Tarmogen yeast vector technology. In contrast to widely used HBV preventive vaccines, therapeutic vaccines are designed to stimulate the body's immune response to the virus, and may be used in conjunction with oral antiviral drugs. 
Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 04 June 2010 12:49
- Written by Dynavax
Dynavax Technologies announced this week that a Data Safety Monitoring Board has reviewed interim data from more than 2000 participants in 2 Phase 3 studies of the company's investigational hepatitis B vaccine, Hepislav, and determined that the trial may go forward without modification.
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 April 2011 03:38
- Written by Liz Highleyman
Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.
EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- Details
- Category: HBV Treatment
- Published on Tuesday, 20 April 2010 13:55
- Written by Liz Highleyman
Combination therapy using tenofovir (Viread) plus emtricitabine (Emtriva) -- the 2 drugs in the Truvada coformulation -- either with or without injected hepatitis B virus (HBV) antibodies, was well tolerated and prevented HBV recurrence in chronic hepatitis B patients with mild-to-moderate kidney (renal) impairment who underwent liver transplantation, according to a study presented last week at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna.
Web Design and Development by